Familial Cancer

, Volume 10, Issue 2, pp 365–371 | Cite as

Novel germline SDHD mutation: diagnosis and implications to the patient

  • Jeena Varghese
  • Montserrat Ayala-Ramirez
  • Thereasa Rich
  • Eric Rohren
  • Priya Rao
  • Camilo Jimenez


A 54-year-old man presented with hypertensive crisis. He was found to have bilateral pheochromocytomas and left paraaortic sympathetic paraganglioma. Although he had no family history of paragangliomas or pheochromocytomas, he had been diagnosed with bilateral head and neck paragangliomas 10 years prior. The patient had symptoms of catecholamine excess exacerbated by vanilla ice-cream consumption. Biochemical testing revealed elevated plasma-free metanephrines and chromogranin A levels. Computed tomography showed bilateral carotid body tumors and four reteroperitoneal masses (two in the right adrenal, one in the left adrenal and one in the left paraaortic area). Metaiodobenzylguanidine-SPECT scans showed functional tumors in both the adrenal gland and left paraaortic area. Fluorine 18-fluorodeoxyglucose positron emission tomography did not show any visceral or skeletal metastasis. We carried out gene mutation analysis for succinate dehydrogenase complex subunit B, and succinate dehydrogenase complex subunit D. The patient was diagnosed with hereditary paraganglioma syndrome type 1 with a previously unreported subunit D mutation in exon 3 (c.198G > A, p.W66X). He was treated with phenoxybenzamine at 10 mg/day and with metoprolol at 12.5 mg/day. His blood pressures as well as symptoms of catecholamine excess were controlled. He then underwent bilateral adrenalectomy and reteroperitoneal dissection. His blood pressure normalized and he discontinued antihypertensive medications after surgery. He is currently on replacement therapy with hydrocortisone and fludrocortisone.


Paraganglioma type 1 Head and neck paragangliomas Pheochromocytomas Sympathetic paragangliomas SDHD Adrenal insufficiency Flushing and vanilla ice-cream 


mm Hg

Millimeters of mercury


Computed tomography






Multiple endocrine neoplasia


Von Hippel-Lindau disease


Fluorine 18 (18F)-fluorodeoxyglucose


Positron emission tomography


Succinate dehydrogenase


Paraganglioma syndrome type 1


Magnetic resonance imaging


  1. 1.
    DeLellis RA, Lloyd RV, Heitz PU, Eng C (2004) Pathology and genetics of tumours of endocrine organs. In: Kleihues P, Sobin LE (eds) World health organization classification of tumours, vol 8. IARC Press, Lyon, pp 138–159Google Scholar
  2. 2.
    Neumann HP, Bausch B, McWhinney SR et al (2002) Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346(19):1459–1466PubMedCrossRefGoogle Scholar
  3. 3.
    Jimenez C, Cote G, Arnold A, Gagel RF (2006) Review: Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes? J Clin Endocrinol Metab 91(8):2851–2858PubMedCrossRefGoogle Scholar
  4. 4.
    Hao HX, Khalimonchuk O, Schraders M et al (2009) SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science 325(5944):1139–1142PubMedCrossRefGoogle Scholar
  5. 5.
    Qin Y, Yao L, King EE et al (2010) Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet 42(3):229–233PubMedCrossRefGoogle Scholar
  6. 6.
    Favier J, Briere JJ, Strompf L et al (2005) Hereditary paraganglioma/pheochromocytoma and inherited succinate dehydrogenase deficiency. Horm Res 63(4):171–179PubMedCrossRefGoogle Scholar
  7. 7.
    Burnichon N, Briere JJ, Libe R et al (2010) SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet 19(15):3011–3020PubMedCrossRefGoogle Scholar
  8. 8.
    King A, Selak MA, Gottlieb E (2006) Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene 25(34):4675–4682PubMedCrossRefGoogle Scholar
  9. 9.
    Bayley JP, Devilee P, Taschner PE (2005) The SDH mutation database: an online resource for succinate dehydrogenase sequence variants involved in pheochromocytoma, paraganglioma and mitochondrial complex II deficiency. BMC Med Genet 6:39PubMedCrossRefGoogle Scholar
  10. 10.
    van Nederveen FH, Gaal J, Favier J et al (2009) An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 10(8):764–771PubMedCrossRefGoogle Scholar
  11. 11.
    Neumann HP, Pawlu C, Peczkowska M et al (2004) Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292(8):943–951PubMedCrossRefGoogle Scholar
  12. 12.
    Ricketts CJ, Forman JR, Rattenberry E et al (2009) Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum Mutat 31(1):41–51CrossRefGoogle Scholar
  13. 13.
    Hensen EF, Jordanova ES, van Minderhout IJ et al (2004) Somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families. Oncogene 23(23):4076–4083PubMedCrossRefGoogle Scholar
  14. 14.
    Erlic Z, Neumann HP (2009) Familial pheochromocytoma. Hormones (Athens) 8(1):29–38Google Scholar
  15. 15.
    Lenders JW, Pacak K, Walther MM et al (2002) Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 287(11):1427–1434PubMedCrossRefGoogle Scholar
  16. 16.
    Eisenhofer G, Pacak K, Huynh TT et al (2011) Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocr Relat Cancer 18(1):97–111PubMedCrossRefGoogle Scholar
  17. 17.
    Brink I, Hoegerle S, Klisch J, Bley TA (2005) Imaging of pheochromocytoma and paraganglioma. Fam Cancer 4(1):61–68PubMedCrossRefGoogle Scholar
  18. 18.
    Timmers HJ, Kozupa A, Chen CC et al (2007) Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol 25(16):2262–2269PubMedCrossRefGoogle Scholar
  19. 19.
    Ayala-Ramirez M, Callender GG, Kupferman ME et al (2010) Paraganglioma syndrome type 1 in a patient with Carney-Stratakis syndrome. Nat Rev Endocrinol 6(2):110–115PubMedCrossRefGoogle Scholar
  20. 20.
    Ayala-Ramirez M, Feng L, Johnson MM et al (2010) Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. doi: 10.1210/jc.2010-1946
  21. 21.
    Yip L, Lee JE, Shapiro SE et al (2004) Surgical management of hereditary pheochromocytoma. J Am Coll Surg 198(4):525–534 discussion 34-5PubMedCrossRefGoogle Scholar
  22. 22.
    Peczkowska M, Erlic Z, Hoffmann MM et al (2008) Impact of screening kindreds for SDHD p.Cys11X as a common mutation associated with paraganglioma syndrome type 1. J Clin Endocrinol Metab 93(12):4818–4825PubMedCrossRefGoogle Scholar
  23. 23.
    Havekes B, van der Klaauw AA, Weiss MM et al (2009) Pheochromocytomas and extra-adrenal paragangliomas detected by screening in patients with SDHD-associated head-and-neck paragangliomas. Endocr Relat Cancer 16(2):527–536PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Jeena Varghese
    • 1
  • Montserrat Ayala-Ramirez
    • 1
  • Thereasa Rich
    • 2
  • Eric Rohren
    • 3
  • Priya Rao
    • 4
  • Camilo Jimenez
    • 1
  1. 1.Departments of Endocrine Neoplasia and Hormonal Disorders, Unit 1461The University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Departments of Surgical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  3. 3.Departments of Nuclear MedicineThe University of Texas MD Anderson Cancer CenterHoustonUSA
  4. 4.Departments of PathologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations